Coeptis Therapeutics Holdings Inc., a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, has expanded its technological initiatives to include artificial intelligence and blockchain solutions.

After launching its Technology Division and introducing AI capabilities, Coeptis has demonstrated promise in enhancing operational efficiency and customer engagement. The Company recognizes the enormous potential for AI to revolutionize the pharmaceutical landscape while exploring the opportunities provided by blockchain technology.

Dave Mehalick, President and CEO of Coeptis, stated, “We are thrilled to build upon the momentum we’ve generated with our Technology Division, particularly in the area of artificial intelligence, as we look to advance our initiatives leveraging blockchain technology. This expansion signifies not only our commitment to remaining at the forefront of technological developments but also our dedication to exploring new avenues that align with the rapidly evolving digital marketplace.”

“The integration of blockchain initiatives into the Technology Division’s portfolio reflects Coeptis’s mission to adapt to emerging trends and leverage new market opportunities for enhanced value creation,” added Mr. Mehalick. As we embark on this new journey, we are confident in our ability to drive innovation and explore synergies that will benefit our customers and shareholders.